How JAK Inhibitors Revolutionized Dermatology Care
Last summer, Derm Discussions host Brad Glick, DO, invited Brett King, MD, PhD, Yale School of Medicine, to the program to discuss an emerging class of dermatology therapy known as Janus kinase (JAK) inhibitors.
At the time, small molecule drugs such as upadacitinib (Rinvoq) were approved for the treatment of conditions like rheumatoid arthritis and ulcerative colitis.
Since then, updacacitin...
14m
•
Apr 19, 2022